⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 1, 2024Open Access

Supplementary Figure S2 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

Ana Oaknin Sharad Ghamande Yuka Kasamatsu Marta Gil-Martín Juan Francisco Grau-Béjar Carmen García-Durán Masashi Sato Abdul Siddiqui Surendra Pal Chaudhary Yulia Vugmeyster Kosei Hasegawa

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S2. Change from baseline in sum of diameters of all target lesions per RECIST v1.1 for Cohort 2. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oaknin et al. (2024) studied this question.

synapsesocial.com/papers/68e76734b6db6435876dc9cc https://doi.org/10.1158/1078-0432.25324506

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer2024
2Supplementary Figure S1 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer2024
3Supplementary Figure S4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer2025
4Supplementary Figure S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer2024
5Supplementary Figure S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer2024